22nd Century Group reiterated their reiterates rating on shares of Mirati Therapeutics ( NASDAQ:MRTX – Get Rating ) in a report released on Thursday, Benzinga reports. Several other research firms also recently issued reports on MRTX. BMO Capital Markets reduced their price target on shares of Mirati Therapeutics from $59.00 to $50.00 and set a market perform rating for the company in a research report on Wednesday, March 1st. StockNews.com started coverage on shares of Mirati Therapeutics in a report on Thursday, March 16th.

https://www.dailypolitical.com/2023/05/15/mirati-therapeutics-mrtx-reiterates-rating-reaffirmed-at-22nd-century-group.html

#dailypolitical